BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye X, Tateno C, Thi EP, Kakuni M, Snead NM, Ishida Y, Barnard TR, Sofia MJ, Shimada T, Lee ACH. Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model. ACS Infect Dis 2019;5:738-49. [PMID: 30408957 DOI: 10.1021/acsinfecdis.8b00192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ge X, Chen L, Zhao B, Yuan W. Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA. Front Pharmacol 2020;11:598175. [PMID: 33716725 DOI: 10.3389/fphar.2020.598175] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pacin-ruiz B, Cortese MF, Tabernero D, Sopena S, Gregori J, García-garcía S, Casillas R, Najarro A, Aldama U, Palom A, Rando-segura A, Galán A, Vila M, Riveiro-barciela M, Quer J, González-aseguinolaza G, Buti M, Rodríguez-frías F. Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability. Viruses 2022;14:215. [DOI: 10.3390/v14020215] [Reference Citation Analysis]
3 Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101. [PMID: 32561705 DOI: 10.1038/s41392-020-0207-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 49.5] [Reference Citation Analysis]
4 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
5 Niculescu AG, Bîrcă AC, Grumezescu AM. New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery. Pharmaceutics 2021;13:2053. [PMID: 34959335 DOI: 10.3390/pharmaceutics13122053] [Reference Citation Analysis]
6 Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev 2021;178:113834. [PMID: 34492233 DOI: 10.1016/j.addr.2021.113834] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliv Rev 2020;154-155:37-63. [PMID: 32526452 DOI: 10.1016/j.addr.2020.06.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 19.0] [Reference Citation Analysis]
8 Dash PK, Gorantla S, Poluektova L, Hasan M, Waight E, Zhang C, Markovic M, Edagwa B, Machhi J, Olson KE, Wang X, Mosley RL, Kevadiya B, Gendelman HE. Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology 2021;18:13. [PMID: 34090462 DOI: 10.1186/s12977-021-00557-1] [Reference Citation Analysis]
9 Giersch K, Dandri M. In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? Viruses 2021;13:588. [PMID: 33807170 DOI: 10.3390/v13040588] [Reference Citation Analysis]
10 Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev 2020;159:344-63. [PMID: 32622021 DOI: 10.1016/j.addr.2020.06.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]